Earnings|Abbott India Ltd (NSE:ABBOTTINDIA) : Q3FY23 Results Out; Total Income rise 10% YoY

Abbott India Ltd (NSE:ABBOTTINDIA) is a subsidiary of the global healthcare company, Abbott Laboratories. It was established in 1944 and is headquartered in Mumbai, India. The company’s products and services include pharmaceuticals, medical devices, and diagnostics. Abbott India provides a range of medicines across multiple therapeutic areas such as gastroenterology, women’s health, neurology, and more. The company also offers medical devices for areas such as diabetes care, nutritional supplements, and diagnostic products for various diseases. Abbott India’s mission is to improve the health and well-being of people in India and to become the most valued healthcare company in the country.

Abbott India Ltd, reported strong financial results for the period ended December 31, 2021. Despite a slower revenue growth rate of 8.3% compared to Q2FY23, the company’s net income exceeded expectations. Abbott India’s PAT surged 23.9%, and its EBITDA margin expanded by 188 basis points year-on-year to 23.9%.

The company’s operating performance was strong, with major operating costs declining year-on-year, driving up EBITDA margins. Gross margins, however, fell by 320 basis points. The company’s employee and other expenses also decreased year-on-year as a percentage of revenue.

Abbott India’s total income for the period ended December 31, 2021, was Rs. 1243.10 crores, compared to Rs. 1110.38 crores during the period ended December 31, 2020. The company’s net profit for the period ended December 31, 2021, was Rs. 199.20 crores, compared to Rs. 177.14 crores during the same period in the previous year. The company’s EPS for the period ended December 31, 2021, was Rs. 93.74, compared to Rs. 83.36 for the period ended December 31, 2020.

The company’s revenues and earnings are projected to grow at a CAGR of 11.0% and 19.0%, respectively, over the period FY2022-FY2025E, due to healthy growth prospects and a strong brand equity. Abbott India is expected to benefit from growth opportunities in the Indian healthcare sector, including rising demand for quality healthcare, increased access to healthcare services, and increased spending on healthcare.

Overall, Abbott India’s strong financial results reflect the company’s successful execution of its growth strategy and its focus on delivering innovative healthcare products and services that meet the needs of Indian consumers.